C1q and Mannose Binding Lectin Engagement of Cell Surface Calreticulin and Cd91 Initiates Macropinocytosis and Uptake of Apoptotic Cells by Ogden, Carol Anne et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/09/781/15 $5.00
Volume 194, Number 6, September 17, 2001 781–795
http://www.jem.org/cgi/content/full/194/6/781
 
781
 
C1q and Mannose Binding Lectin Engagement of Cell 
Surface Calreticulin and CD91 Initiates Macropinocytosis 
and Uptake of Apoptotic Cells
 
Carol Anne Ogden,
 
1
 
 Aimee deCathelineau,
 
1
 
 Peter R. Hoffmann,
 
1
 
 
Donna Bratton,
 
1
 
 Berhane Ghebrehiwet,
 
2
 
 Valerie A. Fadok,
 
1
 
and Peter M. Henson
 
1
 
1
 
Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206
 
2
 
Department of Medicine, Health Sciences Center, State University of New York, Stony Brook, Stony 
Brook, NY 11794
 
Abstract
 
Removal of apoptotic cells is essential for maintenance of tissue homeostasis, organogenesis, re-
modeling, development, and maintenance of the immune system, protection against neoplasia,
and resolution of inflammation. The mechanisms of this removal involve recognition of the ap-
optotic cell surface and initiation of phagocytic uptake into a variety of cell types. Here we
provide evidence that C1q and mannose binding lectin (MBL), a member of the collectin fam-
ily of proteins, bind to apoptotic cells and stimulate ingestion of these by ligation on the phago-
cyte surface of the multifunctional protein, calreticulin (also known as the cC1qR), which in
turn is bound to the endocytic receptor protein CD91, also known as the 
 
 
 
-2-macroglobulin
receptor. Use of these proteins provides another example of apoptotic cell clearance mediated
by pattern recognition molecules of the innate immune system. Ingestion of the apoptotic cells
through calreticulin/CD91 stimulation is further shown to involve the process of macropi-
nocytosis, implicated as a primitive and relatively nonselective uptake mechanism for C1q- and
MBL-enhanced engulfment of whole, intact apoptotic cells, as well as cell debris and foreign
organisms to which these molecules may bind.
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Introduction
 
Collectins, also known as defense collagens, are a multi-
functional family of proteins with C-type lectin domains
and pattern recognition capability thought to be involved
in the role of the innate immune system in protection from
infectious organisms (1, 2). Members of the family include
 
mannose binding lectin (MBL),
 
*
 
 surfactant proteins A and
D (SP-A and SP-D), and bovine conglutinin. C1q, a mem-
ber of the first component of the classical complement
pathway, is related to this family as it shares structural and
functional homology with the collectins, although it does
not exhibit lectin activity (3).
C1q deficiency is known to result in an increased risk for
bacterial infections and autoimmune diseases such as sys-
temic lupus erythematosus (SLE; references 4–7) and lupus
nephritis (8). MBL deficiency is also associated with an in-
creased susceptibility to infection and disease (9–11). For
example, recent findings have shown a correlation between
MBL deficiency and 
 
Pseudomonas
 
 infections in cystic fibro-
sis patients, suggesting that MBL is inherently involved in
clearance of potential pathogens in the body (12).
C1q knockout mice exhibit a phenotype resembling
some aspects of SLE. These mice develop autoantibodies
and glomerulonephritis due to immune complex deposi-
tion, which may be exacerbated by the presence of multi-
ple apoptotic bodies (13). Abnormal clearance of apoptotic
cells with inappropriate levels of apoptotic nuclei have
been suggested to contribute to SLE (14) and the knockout
mice also show a defect in clearance of apoptotic cells in
vivo (15). As C1q has been shown to recognize and bind to
surface blebs on apoptotic keratinocytes (16), and apoptotic
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vascular endothelial cells (17), we questioned the potential
role of C1q and the related protein MBL as mediators of
apoptotic cell recognition and clearance and have begun to
examine mechanisms of this engulfment.
Our studies demonstrate that C1q and MBL can bind to,
and initiate uptake of, apoptotic cells into macrophages. In
addition, evidence is provided to support a role for cell sur-
face calreticulin (CRT) in (also known as the cC1qR)
binding the collagenous tails of C1q and MBL attached to
the apoptotic cell. This multifunctional protein does not
have a transmembrane domain but appears to signal for ap-
optotic cell ingestion through association with CD91 (also
known as the 
 
 
 
2-macroglobulin (
 
 
 
2m) receptor or LDL
receptor related–protein (LRP) on the macrophage cell
surface. This is suggested to initiate engulfment of the ap-
optotic cells by a process leading to concurrent uptake of
extracellular fluid and the formation of spacious phago-
somes. It can also stimulate bystander engulfment of at-
tached cells. Accordingly, uptake of apoptotic cells by these
processes is suggested to occur by macropinocytosis.
 
Materials and Methods
 
Phagocytosis Assays.
 
Human monocytes were isolated on a
Percoll gradient as described previously (18) and then washed
twice in HBSS (Cellgro). They were resuspended in X-Vivo me-
dia (Biowhittaker) to a final concentration of 4 
 
  
 
10
 
6
 
 cells/ml
and allowed to adhere in 48-well plates (0.5 ml/well) for 1 h at
37
 
 
 
C with 10% CO
 
2
 
. At this point, medium was changed to
X-Vivo plus 10% heat-inactivated, pooled human serum. The
cells were allowed to mature into macrophages over a 7–10-d pe-
riod, with the medium changed at days 4 and 7. The macro-
phages were used after 7 d of culture.
Jurkat T cells were cultured in RPMI (Cellgro) plus 10% heat-
killed fetal calf serum (Gemini) and penicillin/streptomycin plus
 
l
 
-glutamine (Sigma-Aldrich). Prior to phagocytosis, the cells
were irradiated with UV (254 nm) for 10 min, then cultured at
37
 
 
 
C plus 5% CO
 
2
 
 for 3 h to induce apoptosis. The cells were
washed with HBSS and resuspended in DMEM (Cellgro). The
percentage apoptosis was routinely determined (usually 65–70%)
by morphologic assessment of nuclear alterations after cytocen-
trifugation and staining with a modified Wright-Giemsa stain.
Apoptosis was confirmed by propidium iodide staining for sub-
diploid DNA and by the ability to bind annexin V-FITC.
The human monocyte-derived macrophages (HMDMs) were
treated with inhibitors half an hour before the addition of apop-
totic cells. Antibodies to block uptake were added at a final con-
centration of 10 
 
 
 
g/ml and the cells incubated at 37
 
 
 
C in 10%
CO
 
2
 
 for 30 min. The wells were washed with HBSS and apop-
totic cells added for 1 h at 37
 
 
 
C. After removal of noningested
apoptotic cells with PBS (Cellgro), the cells were then fixed and
counted for uptake.
Uptake conditions and assessment have been described previ-
ously (19). The data are presented as a phagocytic index calcu-
lated as: (no. Møs with ingested apoptotic cells/total no. Møs) 
 
 
 
(no. apoptotic cells per Mø/no. Møs with apoptotic cells).
Using this phagocytic index, data from experimental wells
were compared with controls with no inhibitor or antibody
added.
Inhibitors used included the following: anti-C1q, monoclonal
from Quidel Corp. Sheep and goat polyclonal from ICN Bio-
 
medicals. Monoclonal anti-MBL was provided by Statens Serum
Institut, Copenhagen, Denmark. Anti-C1qRp antibodies were
provided by Andrea Tenner, University of California Irvine,
CA. Monoclonal anti-CR1 (anti-CD35), anti-mannose receptor,
anti-CD32 (BD PharMingen); monoclonal anti-CR3 (Dako);
chicken polyclonal anti-CRT antibodies (Affinity BioReagents,
Inc.); rabbit polyclonal anti-CRT (Upstate Biochemicals); rabbit
polyclonal anti-cC1qR (from Dr. Ghebrehiwet); mouse anti–
human CD91 (
 
 
 
 chain) and anti-CD91 (
 
 
 
 chain) monoclonal
antibodies (American Diagnostica); (all antibodies anti–human).
Control antibodies consisted of monoclonal and polyclonal anti-
CD45 antibodies (BD PharMingen and The Binding Site, respec-
tively); chicken IgY and human Ig, as well as FITC-conjugated
goat anti–mouse IgG and Cy3-conjugated donkey anti–chicken
IgY (Jackson ImmunoResearch Laboratories).
Purified human C1q was obtained from Quidel Corp. MBL
was purified from acute-phase human plasma (obtained from
Bonfils Blood Center, Denver, CO) as reported previously (20).
C1q collagenous tails were prepared following a modified proto-
col from reference 21. Briefly, C1q was dialyzed overnight
against 0.15 M NaCl, 0.1M NaAcetate, pH 4.5, and incubated
for 4 h at 37
 
 
 
C with a 1:30 dilution of 10 mg/ml pepsin. After
centrifugation for 10 min at 10,000 
 
g
 
, the supernatant was frac-
tionated on an ACA34 column and tails eluted with Tris-buffered
saline with 5 mM Ca
 
2
 
 
 
. 1-ml aliquots were collected; tails were
usually eluted around fraction 6. Human 
 
 
 
-2-macroglobulin and
bovine CRT were obtained from Sigma-Aldrich.
 
Surface Modulation Experiments.
 
Proteins were resuspended in
DMEM to a concentration of 0.1 
 
 
 
g/ml and 100 
 
 
 
l added per
well of a 48-well plate and kept at 4
 
 
 
C for 2 h. The plate was
then warmed to 37
 
 
 
C, and 100 
 
 
 
l of a solution 5 
 
 
 
 10
 
6
 
 HMDMs
was plated on each well. These were obtained by maturing hu-
man monocytes as before but on 10-cm bacteriologic plates at
40 
 
 
 
 10
 
6
 
 cells/well for 7 d. The plates were placed on ice with
HBSS
 
 
 
plus 10 mM EDTA for 15 min and cells harvested using
cell lifters and washed twice with HBSS. These HMDMs were
allowed to adhere on the proteins for 30 min at 37
 
 
 
C before add-
ing apoptotic cells. Phagocytosis was allowed to occur for 1 h,
and then cells were washed, fixed, and counted.
 
Flow Cytometry.
 
Cells were resuspended to 10 
 
 
 
 10
 
6
 
 cells per
ml in HBSS and 100 
 
 
 
l pipetted into each well of a 96-well,
U-bottomed plate. The plates were centrifuged at 1,000 RPM
for 2 min at 4
 
 
 
C. After two washes with Kreb’s/Ringers phos-
phate and dextrose buffer (containing 0.9% NaCl, 1.15% KCl,
0.61% CaCl
 
2
 
, 3.82% MgSO
 
4
 
.7H2O, 0.2 M NaH
 
2
 
PO
 
4
 
, 0.2 M
Na
 
2
 
HPO
 
4
 
, and dextrose; pH adjusted to 7.34; KRPD) plus
0.25% human serum albumin, the cells were resuspended in this
buffer with FITC-conjugated protein (prepared using the Fluo-
roTag™ FITC conjugation kit; Sigma-Aldrich), or with 5 
 
 
 
g
primary antibody (rabbit anti-CRT or rabbit immunoglobulin;
Jackson ImmunoResearch Laboratories) for 1 h on ice in the
dark. Cells stained with antibody were then washed twice and re-
suspended in buffer and secondary antibody (1:200; FITC don-
key anti–rabbit; Jackson ImmunoResearch Laboratories). These
cells were incubated on ice, in the dark for 30 min, and then
washed. After two washes, the cells were resuspended in 1 ml of
buffer and analyzed on a FACScan™ (Becton Dickinson). The
data were analyzed using PC Lysis software (Becton Dickinson).
 
Construction of Single Ligand Particles for Uptake (E
 
bab
 
).
 
Human
erythrocytes were obtained from normal donors and washed in
1
 
 
 
 PBS, pH 8.0. 30 
 
  
 
10
 
6 
 
erythrocytes were resuspended in 800
 
 
 
l PBS, pH 8.0, and incubated with EZ-Link Sulfo-NHS-LC-
Biotin (Pierce Chemical Co.) according to manufacturer’s in- 
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structions. These biotinylated erythrocytes (E
 
b
 
) were washed
twice, resuspended in 1
 
 
 
 PBS, pH 8.0, and incubated with 120
 
 
 
g streptavidin (Sigma-Aldrich) at room temperature for 30 min.
E
 
bab
 
 were washed twice, resuspended in 1
 
 
 
 PBS, pH 7.4, and in-
cubated with 5–10 
 
 
 
g of biotinylated antibody or protein. Proper
construction and equal ligand distribution of E
 
bab
 
 was confirmed
by flow cytometry using the appropriate fluorochrome-conju-
gated antibody.
 
E
 
bab
 
 Phagocytosis Assays.
 
Serum-containing media was washed
from cells and replaced with DMEM. Target E
 
bab
 
 were added to
macrophages at a ratio of 15:1 and allowed to incubate at 37
 
 
 
C
for 30 min. Unbound E
 
bab
 
 were washed away with HBSS. Lysis
of uningested E
 
bab
 
 was performed by adding deionized H
 
2
 
O for
10 s, followed by immediate replacement with DMEM. Cells
were fixed with 0.75% glutaraldehyde, stained with dianisidine
and H
 
2
 
O
 
2
 
 (Sigma-Aldrich), and counterstained with eosin. 200
cells were scored using light microscopy to quantify binding (be-
fore distilled water lysis) and engulfment of E
 
bab
 
 (after lysis).
 
Fluorescence Microscopy.
 
Macrophages were plated onto cov-
erslips in 24-well plates and allowed to mature over 7 d (10
 
6
 
cells/coverslip). The cells were washed twice with KRPD plus
0.25% heat stable antigen (HSA) buffer, and incubated in 0.5 ml
buffer plus 1 
 
 
 
g human gamma globulin for 20 min on ice. The
cells were washed twice, and then incubated in 0.5 ml of buffer
plus 10 
 
 
 
g primary antibody (mouse anti–human CD45, BD
PharMingen; chicken anti–human CRT, Affinity Bioreagents,
Inc.; mouse anti–human CD32, BD PharMingen; mouse anti-
CD91, American Diagnostica) for 1 h on ice. The cells were
washed twice and incubated in 0.5 ml of buffer plus secondary
antibody (FITC anti–mouse and Cy3 anti–chicken; Jackson Im-
munoResearch Laboratories; 1:200) for 30 min on ice in the
dark. The cells were then washed twice, and the coverslips re-
moved from the wells and mounted onto slides and visualized by
confocal microscopy.
Jurkat cells (viable or apoptotic) were resuspended to 10 
 
 
 
 10
 
6
 
cells per ml in HBSS and 100 
 
 
 
l pipetted into each well of a 96-
well, U-bottomed plate. The plates were centrifuged in plate
spinners at 1,000 RPM for 2 min at 4
 
 
 
C. After two washes with
Kreb’s/Ringers phosphate and dextrose buffer (KRPD) plus
0.25% human serum albumin, the cells were resuspended in this
buffer with 5 
 
 
 
g FITC-conjugated protein (prepared using
FITC-conjugation kit; Sigma-Aldrich) for 1 h on ice in the dark.
Cells were then washed twice, resuspended in buffer, mounted
onto slides coated with GelMount (Biomeda), and visualized by
confocal microscopy. A directly labeled FITC C1q or MBL
(shown), unlabeled C1q or MBL with fluorochrome-conjugated
polyclonal anti-C1q or monoclonal anti-MBL (not shown), or a
biotinylated C1q or MBL and fluorochrome-conjugated strepta-
vidin (not shown); all gave identical results.
 
Stimulated Macropinocytosis Experiments (Uptake of Lucifer Yel-
low).
 
HMDMs were incubated with 10 
 
 
 
g/ml anti-CRT anti-
CD91 or, as control, anti-CD45 antibodies for 15 min at 37
 
 
 
C. In
some experiments, appropriate cross-linking anti-immunoglobu-
lin antibodies (5 
 
 
 
g/ml) were then added for an additional 10
min. Lucifer Yellow was then added to the medium (to a final
concentration of 1.5 mg/ml) for 2 min as the cells were incubated
at room temperature, in the dark, on a rocking surface. The cells
were then washed and fixed in paraformaldehyde before being
mounted onto coverslips and visualized via confocal microscopy.
 
Bystander Uptake Experiments.
 
RBCs coated with anti-CD36
were prepared as described above. These were added to HMDMs
and allowed to adhere at 37
 
 
 
C for 15 min (although the E
 
bab
 
-
anti-CD36 cells became tethered to the macrophages, uptake did
 
not occur). Antibodies to human CRT or CD91 present on the
macrophage surface were added followed by buffer, or in some
experiments, cross-linking anti–chicken immunoglobulin. Cross-
linked mouse anti–human CD45 (anti-CD45) was used as a con-
trol. The cells were incubated for a further 30 min at 37
 
 
 
C. Cells
were then washed, fixed, stained, and counted.
 
Concurrent Ingestion of Extracellular Fluid Marker.
 
Erythrocytes
were prepared as described. Texas Red succinimidyl ester dye
(Molecular Probes) was incubated with the erythrocytes for 25
min at 37
 
 
 
C. HMDMs, plated in wells containing sterile cover-
slips, were washed with HBSS, and incubated in X-vivo medium
for 2 h before assay. Erythrocytes were washed and added to se-
rum-starved macrophages along with Lucifer Yellow dye (Molec-
ular Probes). Phagocytosis was allowed to occur for 15 min in the
dark and at 37
 
 
 
C. Cells were washed, and incubated in PBS and
DAPI (Calbiochem) stain for 10 min in the dark at room temper-
ature. Cells were washed, fixed in paraformaldehyde, mounted
onto slides, and visualized by confocal microscopy.
Statistical analysis was performed by the one-way analysis of
variance (Anova) and Dunnett’s comparison of means using JMP
3.2.6 software (SAS Institute). 
 
*
 
 denotes statistical significance. A
value is deemed significant if 
 
P
 
 
 
  
 
0.05.
 
Results
 
C1q and MBL Recognize Apoptotic Cells.
 
C1q has been
reported to bind to surface blebs on apoptotic human kera-
tinocytes (16) and apoptotic vascular endothelial cells (17).
We show here that C1q also attaches to blebs on apoptotic
Jurkat T cells (Fig. 1 A). While binding was also seen with
nonapoptotic cells, the distribution in this circumstance
was uniform over the cell surface without the high-density
localization apparent on the apoptotic cells. This high local
concentration of C1q binding may be important in interac-
tion with the phagocyte receptor. On the other hand,
MBL bound preferentially to apoptotic Jurkat T cells com-
pared with fresh control cells (Fig. 1 B).
The experiments herein were performed using apoptotic
Jurkat T cells (shown) or apoptotic human neutrophils (not
shown), and comparable results were obtained with both
cell types. Specific ligands on the apoptotic cells for these
two proteins have not been identified, but pretreatment
with mannosidase or inclusion of high concentrations of
mannose (20 mM) in the medium both reduced apoptotic
cell uptake and attachment of MBL to the apoptotic cells
(data not shown) and support the concept that MBL is
binding by virtue of its globular head groups. As isolated
C1q collagenous tails did not bind to the apoptotic Jurkat
T cells (data not shown), it is suggested that for C1q, too, it
is the globular heads that recognize the apoptotic cell sur-
face; however, the ligand to which it binds is not known.
 
Apoptotic Cell Uptake Mediated by C1q or MBL.
 
Delib-
erate preincubation of either C1q or MBL with the target
apoptotic cells enhanced uptake of these cells by HMDMs
(Fig. 2 A). While the observation supports the concept of
apoptotic cell “opsonization” by the two collectin family
members, there was significant uptake even in the absence
of added C1q or MBL. In part this may be explained by the
ability of the macrophages to synthesize their own C1q
which seems to contribute to the uptake. They may also be 
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able to synthesize MBL (preliminary data not shown).
Thus, even in the absence of added C1q or MBL, antibod-
ies to each of these proteins were able to partially reduce
uptake of apoptotic Jurkat T cells (Fig. 2 B). Second, C1q
and MBL-mediated uptake is not the only process in-
volved. A number of other ligands and receptors may be
active (19, 22–46), including a receptor for phosphati-
dylserine (47). To obviate this difficulty, we have recently
developed a system to examine single ligands in order to
address receptor usage and mechanisms of ingestion. A
sandwich is created on human erythrocytes with biotin,
streptavidin, and then a final coating of the biotinylated
protein of interest, whether antibody or natural ligand (un-
published data). The erythrocytes neither bind nor are in-
gested without appropriate ligands. Moreover, hypotonic
lysis can be used to distinguish bound from ingested cells
(48). Erythrocytes coated with biotinylated BSA (Sigma-
Aldrich) were used as a negative control; these cells neither
bind to nor are taken up by macrophages. As depicted in
Fig. 2 C, erythrocytes (coated with C1q, C1q collagenous
tails, or with MBL) bound to, and were ingested by, hu-
man macrophages.
 
Phagocyte “Receptors” for the Collagenous Tails of C1q and
MBL — The Role of CRT.
 
Macrophages plated on sur-
faces coated with purified C1q, the collagenous “tail” do-
main of C1q, or MBL before the addition of apoptotic tar-
gets, exhibited a decreased uptake of apoptotic Jurkat T
 
cells, in contrast to cells plated on control proteins (Fig. 3
A). Modulation of surface receptors for C1q and MBL on
the cell surface is suggested. The ability of C1q tails to
modulate uptake in this system, or to induce uptake when
attached to erythrocytes (Fig. 2 C), supports a model in
which the C1q and MBL bind to apoptotic cells via their
globular head groups and initiate uptake by interacting
with phagocyte receptors for their structurally homologous
collagenous tail regions.
A number of C1q and collectin receptors have been pro-
posed (1, 49, 50–91). Accordingly, antibodies to many of
these candidate molecules were examined for the ability to
block uptake of apoptotic cells. Only antibodies to the
cC1q receptor (for “collagenous tail C1q receptor”; refer-
ence 65), and CRT, molecules now known to be identical
(49), were able to inhibit uptake (Fig. 3 B). Uptake of
erythrocytes coated with MBL or C1q tails was also
blocked by a variety of different antibodies directed against
CRT, particularly those raised against the N domain of the
molecule. As shown in Fig. 2 C, C1q-coated erythrocytes
were also taken up by the macrophages; however, inhibi-
tion of uptake with anti-CRT was not performed here, for
fear that the globular heads of intact C1q would bind anti-
body nonspecifically, giving a false positive result.
Despite its known role as a chaperone and calcium-
binding protein of the endoplasmic reticulum, CRT has
been demonstrated on the surface of a large number of cell
Figure 1. C1q and MBL bind
to the surface of apoptotic cells.
Both Jurkat T cells and human
neutrophils (not shown) bound
C1q in their fresh and apoptotic
states (A). C1q exhibited diffuse
surface binding to the viable cells,
while it bound in a localized pat-
tern to apparent blebs on the sur-
face of apoptotic cells. MBL
showed little or no binding to
fresh cells and robust, localized
binding to the surface of apoptotic
cells (B). 
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types (55, 92–96) and to bind the collagenous tails of
members of the collectin family, including C1q (2, 97). As
shown in Fig. 3 C, rabbit anti-CRT antibody readily de-
tected this molecule on the surface of HMDMs and this
binding was blocked by pretreatment of the cells with C1q
or C1q collagen tails (not shown). Antibody to human
CD45, used as a positive control for binding, was not pre-
vented from binding to the macrophage cell surface by
C1q tails.
Finally, experiments were performed to support the sug-
gestion that MBL and C1q interact with the same receptor.
As shown in Fig. 3 D, MBL was able to inhibit the binding
of FITC-tagged C1q tails to HMDM surfaces (10 
 
 
 
g/ml
protein used). Irrelevant protein (HSA) had no effect on
C1q tail binding. Conversely, C1q inhibited binding of
FITC-tagged MBL to HMDM surfaces (not shown).
 
A Role for CD91 in Collectin–CRT Signaling for Inges-
tion.
 
While CRT is present on the phagocyte surface, it is
not clear how it gets there. As a protein with no transmem-
brane domain, it also presumably requires a partner to
transduce the signals to initiate engulfment. Recent evi-
dence has been presented by Basu et al. demonstrating the
binding of CRT, as well as various heat shock proteins, to
CD91 on the surface of macrophages (among many other
cell types [98]). This protein, better known as the 
 
 
 
-2-
macroglobulin receptor or LRP, can signal for the endocy-
tosis of adherent proteins. Accordingly it was examined as a
candidate signaling partner for CRT in the C1q and MBL-
mediated uptake of apoptotic cells.
First, CRT and CD91 were seen to colocalize on the
surface HMDM cell membrane (Fig. 4 A). Second, anti-
bodies to CD91 were found to block the uptake of apop-
totic Jurkat T cells by HMDMs (Fig. 4 B), as well as of
erythrocytes carrying C1q tails, a ligand for CRT, or 
 
 
 
2m,
a ligand for CD91 (Fig. 4 C). The ability of anti-CRT
(CRT) pretreatment to reduce uptake of 
 
 2m Ebab suggests
preassociation of CRT with CD91 so that antibody can
modulate/block the CD91/CRT complex and prevent
 2m Ebab binding or engulfment.
In Fig. 5 are depicted receptor modulation experiments
to support the triple involvement of C1q or MBL, CRT,
and CD91. Plating the macrophages on wells precoated
with ligand to CD91,  2m, led to impairment of their abil-
ity to recognize and engulf erythrocytes coated with C1q
tails or  2m (Fig. 5 A); engulfment of anti-CD32 coated
Ebab was unaffected (not shown). These macrophages also
showed reduced uptake of apoptotic cells (Fig. 5 B). Plat-
ing the macrophages on C1q tails had the same effect (Fig.
5, A and B) and, by reducing binding of erythrocytes
coated with  2m, supports the suggestion that these two
molecules are associated on the membrane, are similarly
modulated, and are both required for uptake of C1q- or
Figure 2. C1q and MBL facilitate particle clearance. (A) Pretreatment of ap-
optotic cells with C1q or MBL: apoptotic cells (5   106) were incubated with
50  g of purified C1q or MBL. These cells were tumbled for 30 min at 37 C
and washed with HBSS before addition to macrophages for a phagocytosis assay
(as described in Materials and Methods). n   4   SEM (control mean phagocytic
index   44.2   6.6, P   0.05). (B) Antibody against human C1q and against
human MBL inhibits uptake of apoptotic cells into HMDMs. HMDMs were
treated with 10  g antibody (polyclonal goat anti–human C1q, goat control
antibody, mouse monoclonal anti-CD45 antibody as control, and monoclonal
mouse anti–human MBL, shown) for 30 min at 37 C. Media was then aspi-
rated, and apoptotic cells were added for 1 h for a phagocytosis assay. n   4  
SEM (control mean phagocytic index   37.0   6.1, *P   0.005). (C) C1q,
C1q Tails, or MBL Ebab are ingested by HMDMs. Single ligand coated particles
coated with control protein, MBL, C1q, or the collagenous tail fragment of
C1q were fed to HMDMs for 20 min at 37 C. The cells were then washed,
fixed, and counted (as described in the Materials and Methods section). n  
3   SEM. P   0.005 Engulfed; P   0.003 Adherent.786 C1q or MBL Mediate Macropinocytosis of Apoptotic Cells via CRT or CD91
Figure 3. C1q and MBL facilitate
clearance of apoptotic cells via cell-
surface CRT. (A) Modulation of
membrane receptor(s) by surface-
bound C1q, C1q tails, or MBL.
Macrophages were plated onto wells coated with control protein (HSA),
MBL, C1q, or C1q tails. Apoptotic cells were then added for a phagocy-
tosis assay. n   7   SEM (control mean phagocytic index   38.5   4.4,
P   0.01). (B) Anti-CRT antibodies inhibit uptake of apoptotic cells by
HMDMs. Other anti-receptor antibodies had no effect. anti-Nterm, anti-
CRT, NH2 terminus; anti-Cterm, anti-CRT, COOH terminus; anti-
MR, anti-mannose receptor; anti-CR3, anti-complement receptor 3;
anti-CR1, anti-complement receptor 1. n   4   SEM (control mean
phagocytic index   40.0   4.3, P   0.05). (C) Binding of anti-CRT an-
tibody to the surface of HMDMs. Several polyclonal anti–human CRT
antibodies were found to bind to the surface of HMDMs (see Materials
and Methods) in a similar fashion. Binding of a rabbit anti–human poly-
clonal anti-CRT antibody was blocked by C1q. C1q did not inhibit
binding of irrelevant antibody HMDM surfaces (inset). n   3, representa-
tive experiment shown. (D) MBL and C1q bind to same receptor. C1q
tails were FITC-conjugated (see Materials and Methods) and bound to
HMDM surfaces. Unlabeled, whole MBL decreased this binding when
incubated with the HMDMs along with the FITC-labeled tails, n   3.787 Ogden et al.
MBL-bound cells. Fig. 5 C further supports this hypothesis,
demonstrating an inhibition of clearance of anti-CD91 or
anti-CRT coated Ebab by macrophages plated onto wells
coated with  2m or C1q tails.
Mevorach et al. (46) have reported the opsonization by
serum of apoptotic cells and resultant increase in phagocy-
tosis of these cells by macrophages. Complement compo-
nents present in the serum have been implicated as the op-
sonizing agents. In vivo, C1q and MBL present in the
plasma or inflammatory exudate likely represent the major
source for possible apoptotic cell opsonization. Accord-
ingly, preincubation of the apoptotic cells with serum en-
hanced uptake and, as expected, this was blocked by anti-
CRT and by anti-CD91 antibodies (data not shown).
C1q- or MBL-mediated Engulfment Occurs via CD91-
induced Macropinocytosis. In exploring the mechanisms of
apoptotic cell uptake through the PS receptor we have re-
cently provided evidence that engulfment appeared to oc-
Figure 4. CD91 is involved in C1q- and MBL-mediated uptake via CRT. (A) CRT colocalizes with CD91 on the HMDM cell surface. HMDMs
were stained with chicken anti–human CRT (anti–N-terminus, shown) and mouse anti–human CD91  and   (see Materials and Methods). Antibody
staining was detected with FITC anti–mouse and Cy3 anti–chicken. n   3, representative experiment shown. (B) Uptake of apoptotic cells is inhibited
by antibody to CD91. HMDMs were preincubated with anti-CD91 antibody for 30 min at 37 C. Media was then aspirated and apoptotic cells were
added for 1 h for a phagocytosis assay (see Materials and Methods). anti-CRT, chicken anti-CRT, NH2 terminus; anti-CD91 , anti-CD91,   chain;
anti-CD91 , anti-CD91,   chain. n   3   SEM (control mean phagocytic index   20.3   1.5, P   0.002). (C) C1q tail Ebab and  2m Ebab are taken
up into HMDMs; this uptake is inhibited by anti-CD91 and by anti-CRT. Ebab coated with C1q tails,  2m, or BSA (not shown) were fed to HMDMs
for 20 min at 37 C (see Materials and Methods). n   4. P   0.1 Engulfed; P   0.1 Adherent.788 C1q or MBL Mediate Macropinocytosis of Apoptotic Cells via CRT or CD91
cur by a process of “stimulated phagocytosis” or macro-
pinocytosis (unpublished data). Importantly, surface CRT
or CD91 ligation also appears to initiate macropino-
cytosis. Thus, either anti-CRT or anti-CD91 was shown
capable of inducing uptake of the water-soluble dye Lucifer
Yellow into large macropinosomes within the macrophages
(Fig. 6 A). Antibodies to unrelated surface molecules did
not have this property (some background pinocytosis was
seen in stimulated as well as control macrophages), al-
though the growth factor M-CSF was effective (unpub-
lished data). To confirm the involvement of a stimulated
macropinocytosis mechanism, ligation of CRT or CD91
was used to initiate bystander uptake of previously attached
erythrocytes (Ebab). Ebab were coated with antibodies to an-
other putative apoptotic cell recognition molecule, the B
type scavenger receptor, CD36 (19, 27). The anti-CD36
Ebab became tethered to the macrophage surface but were
not internalized. The addition of soluble anti-CRT or anti-
CD91 antibodies, but not anti-CD32 antibody initiated in-
ternalization of the tethered erythrocytes (Fig. 6 B).
Crosslinking of these antibodies was even more effective.
Finally, erythrocytes were prelabeled with an intracellular
red dye (Texas red succinimidyl ester) and then coated
with antibodies or collectin ligands for uptake. Ingestion by
the macrophages in the presence of Lucifer Yellow led to
phagosomes with coingested dye (Fig. 6 C). This implies a
spacious phagosome with significant concurrent ingestion
of extracellular fluid, an effect more consistent with macro-
pinocytosis (99–102) than with the “zipper” mechanism
used during uptake via the FcR (103, 104). A similar effect
was seen with whole apoptotic cells but in this case could
not definitively be attributed to effects mediated by C1q or
MBL or through CD91 since other processes (e.g., the
phosphatidylserine receptor) may also be operative. The data
support the hypothesis that macropinocytosis is the primary
mechanism for uptake of apoptotic cells.
Discussion
Collectins are proteins of the innate immune system in-
volved in pattern recognition and opsonization of foreign
particles. Recent evidence suggests a role for other mem-
bers of the collectin family, specifically SP-A, in the clear-
ance of apoptotic cells (105).
Here, we propose that a member of this family, MBL,
and a close relative, C1q, bind to apoptotic cells and initiate
Figure 5. CD91 and CRT facilitate particle clearance. (A)  2m and
C1q Tails modulate the uptake of tail Ebab and of  2m Ebab. HMDMs
were plated onto wells coated with either HSA,  2m, or C1q tails (see
Materials and Methods). These macrophages were then fed erythrocytes
coated with C1q tails,  2m, or BSA (not shown) ( 2m/HSA, for exam-
ple, stands for  2m Ebab fed to macrophages plated onto wells coated with
HSA). n   3   SEM. P   0.02 Engulfed. (B)  2m and C1q tails modu-
late the uptake of apoptotic cells. HMDMs were plated onto wells coated
with HSA,  2m, or C1q tails. Apoptotic cells were fed to the macro-
phages for 1 h at 37 C for a phagocytosis assay. n   3   SEM (control
mean phagocytic index  21.3   5.3, P   0.34). (C)  2m or C1q tails
modulate the uptake of anti-CD91 or anti-CRT Ebab. HMDMs were
plated onto wells coated with HSA,  2m, or C1q tails. The macrophages
were then fed erythrocytes coated with BSA, anti-CD32 (neither shown),
anti-CD91, or anti-CRT, NH2 terminus (here, anti-CRT). These Ebab
were incubated with the HMDMs for 20 min. n   3   SEM. P   0.11
Engulfed; P   0.06 Adherent.789 Ogden et al.
their uptake into macrophages. MBL was found to bind
primarily to apoptotic cells and showed little evidence of
interaction with viable cells. C1q has been reported to bind
to the surface of a number of different cell types (55, 106–
112) and here was shown to attach to both viable and ap-
optotic Jurkat T cells. Despite this binding, only apoptotic
cells are engulfed by macrophages. However, a careful ex-
amination of the of C1q binding revealed a clustered distri-
bution on apoptotic cells. This was similar to C1q binding
shown previously on apoptotic keratinocytes (16) or vascu-
lar endothelial cells (17). On viable Jurkat T cells, C1q
binding was diffuse. Reexamination of MBL attachment
suggested a similar distribution on apoptotic cells and im-
plicates significantly altered, but to date uncharacterized,
surface structures on the membrane blebs of apoptotic cells.
The multifunctional properties and binding sites on
Figure 6. Uptake through CRT/CD91 occurs
through a mechanism of macropinocytosis. (A)
Stimulation of CRT and of CD91, but not of
CD45 or CD32, initiate macropinocytosis. Mac-
rophages were incubated in the presence of Luci-
fer Yellow. Anti-CD45 (above right) or anti-
CRT, NH2 terminus (anti-CRT) (bottom right)
were added to the macrophages (5  g/ml) and al-
lowed to interact for 15 min at room tempera-
ture. Cross-linking antibodies were then added
(2.5   g/ml), and the macrophages were incu-
bated with Lucifer Yellow in the dark at 37 C for
5 min. Anti-CRT and anti-CD91 antibodies
stimulated macropinocytosis and subsequent up-
take of Lucifer Yellow dye, whereas anti-CD45
did not. (B) Bystander uptake of adherent parti-
cles by HMDMs occurs via CD91- and CRT-
stimulated macropinocytosis. Chicken anti–human
CRT (N-terminus) or mouse anti–human CD91
were used to stimulate HMDMs with anti-
CD36–coated particles adherent to their surfaces.
Cross-linking antibodies were then added to en-
hance the effect and phagocytosis was allowed to
occur for 20 min. Each bar represents the total
number of adherent cells plus engulfed cells. n  
5   SEM. P   0.0001 Engulfed. (C) Engulfment
of erythrocytes (E) coated with anti-CRT anti-
body involves formation of spacious phagosomes
and concomitant uptake of Lucifer Yellow.
RBCs labeled with anti-CRT, NH2 terminus
(anti-CRT) (i and ii), anti-CD36 (iii), or anti-
CD32 (iv) were stained with Texas red and added
to HMDMs in the presence of Lucifer Yellow.
Anti-CD36 RBCs (iii) were not taken up into
the macrophages, anti-CD32 RBCs (iv) were in-
gested by macrophages, but with no accompany-
ing uptake of Lucifer Yellow. In contrast, anti-
CRT RBCs (i and ii) were taken up into HMDMs
along with Lucifer Yellow, which colocalized in
the same phagosome. HMDM nuclei stained
with DAPI (blue).790 C1q or MBL Mediate Macropinocytosis of Apoptotic Cells via CRT or CD91
MBL and C1q make the orientation of their attachment to
the apoptotic cells difficult to clearly identify. The data pre-
sented herein suggest that for productive initiation of apop-
totic cell engulfment, C1q and MBL bind to the apoptotic
cells by their globular domains and to the phagocyte
through their collagen-like tails.
The globular head regions of the collectins are known to
be involved in pattern recognition and binding and it is
suggested that they interact with the ligands on the surface
of the apoptotic cells. A report of increased mannose ex-
pression on apoptotic hepatocytes and lymphocytes is note-
worthy in this regard (23, 113–115). It can be inferred from
the data that after binding and/or aggregation of the collec-
tins on the apoptotic cell surface, their collagenous tails in-
teract with receptor on the surface of the phagocyte. It
seems likely that this interaction is low affinity and requires
significant aggregation to mediate signaling and uptake.
Complement components have been shown to bind to
and opsonize apoptotic cells (46, 116, 117). Preincubation
of the apoptotic cells with C1q or MBL resulted in some
increased uptake, suggesting opsonization of the target cells
(viable cells, regardless of pretreatment, were not engulfed
by macrophages). However, significant ingestion was seen
even in the absence of prior opsonization and this uptake
was markedly reduced in the presence of anti-C1q or anti-
MBL. The data suggest involvement of the two collectin
family members even in the absence of added protein and
imply production by the macrophages. Macrophages are
known to synthesize and secrete C1q (3) and preliminary
experiments suggest they may produce MBL as well (data
not shown). In vivo, these two proteins will likely be sup-
plied from plasma, and addition of serum to the macro-
phage uptake system did increase the ingestion of apop-
totic, but not viable, cells (data not shown). On the other
hand, not all of the uptake is expected to occur via these
C1q or MBL processes and, as with most attempts to iden-
tify apoptotic uptake receptors by ligand blockade (19, 118,
119), inhibition was never complete.
Preincubation of the phagocytes with the C1q or MBL
before addition of apoptotic targets resulted in a reduced
phagocytic index. Plating macrophages onto wells coated
with C1q or MBL before adding target apoptotic cells
yielded the same result, suggested to reflect modulation of
the phagocytic receptors. The ability of isolated C1q tails to
similarly modulate the functional receptor further supports
the concept that it is this portion of the protein that is pri-
marily recognized by the phagocytes.
The redundancy of recognition and uptake mechanisms
driven by multiple ligands and receptors makes detailed
analysis of any one of these particularly complex. To sim-
plify the examination of C1q- or MBL-induced uptake, a
single ligand-coated particle was used. Human erythrocytes
were coated with biotin (Eb), and a sandwich was created
with avidin and the biotinylated ligand of choice (Ebab-X).
These Ebab cells have a number of advantages, including the
ability to distinguish binding to the phagocyte surface from
engulfment as well as complete absence of binding and en-
gulfment with control erythrocytes. This system demon-
strated that Ebab coated with C1q, MBL, or purified C1q
collagenous tails both bound to, and were directly taken up
into, macrophages.
Several receptors have been postulated to play a role in
C1q- or collectin-mediated uptake of particles by mac-
rophages or other cell types. These include CR1, CR3,
C1qRp, and cC1qR (50, 59–61, 65, 69, 97). Of these,
only antibodies to the cC1qR, or CRT, were found to be
effective in inhibiting phagocytosis of apoptotic cells by
HMDMs. CRT has been shown by several groups to bind
to the collagenous tail regions of MBL, SP-A, conglutinin,
and C1q (1, 74) or SPD (unpublished data). In fact, all anti-
CRT antibodies tested were effective in inhibiting the ap-
optotic cell engulfment, including polyclonal antibodies
produced against the N-domain of the protein, which con-
tains the region shown to bind C1q collagenous tails (78,
120). The efficacy of antibody against the C-domain may
result from blockade of collectin or C1q tail binding or
perhaps as a consequence of receptor modulation. Antibod-
ies to a wide variety of alternative receptors or binding sites
were inactive. Ingestion of Ebab coated with the purified tail
region of C1q, which shares functional homology with the
collagenous tail region of MBL and other collectins, was
also inhibited by antibody against CRT.
Although CRT serves a number of critical functions
within the endoplasmic reticulum (78, 93), it has also been
shown to be expressed on the surface of many cell types,
including human macrophages (49, 84, 86, 96, 121, 122).
Although cultured HMDMs display much phenotypic het-
erogeneity (123), a large portion of the population tested
demonstrated surface expression of CRT. However, the
mode of access to the cell surface and the mechanism of re-
tention at this site is not at all clear — it may be transported
from the endoplasmic reticulum or bind to the cell surface
from the extracellular milieu (98, 124). However, either
route could readily allow for attachment of C1q or MBL
collagenous tails. On the other hand, as CRT is not a trans-
membrane protein, actual signaling for uptake of apoptotic
cells must be presumed to involve some other membrane
structure recruited for the process.
A recent report has suggested that CRT may bind to the
multifunctional receptor, CD91 (98); we show colocaliza-
tion of CRT with CD91 on the HMDM cell surface (Fig.
4 A). This molecule, also known as the  2m receptor or
LRP, is a type 1, 600-kD transmembrane protein made up
of an   and a   chain which are noncovalently, but tightly
attached. Importantly, the receptor has a 100 amino acid
cytoplasm tail that contains two NPXY endocytosis signal
sequences (125). It shares sequence homology in the cyto-
plasmic tail with other receptors used for endocytosis, in-
cluding the newly cloned ced-1 gene from Caenorhabiditis
elegans known to play a role in the phagocytosis of apop-
totic cells in these organisms (126, 127). CD91 is found on
the surface of HMDMs (among many other cell types) and
appeared to be a prime candidate for signaling for apoptotic
cell uptake into these cells. Accordingly, antibodies to
CD91 were found effective in inhibiting uptake of apop-
totic cells, or Ebab coated with MBL, C1q, or C1q collage-791 Ogden et al.
nous tails in exactly the same fashion as shown for anti-
CRT antibodies.
The hypothesis, then, is that CRT acts to bind the col-
lagenous tails of C1q and MBL and then signals for uptake
due to its interaction with CD91. To support this likeli-
hood, a number of different experiments were performed.
Importantly, CD91 could be modulated from the upper
surface of macrophages by plating the cells onto wells
coated with a ligand for this molecule,  2m. Not only
were the upper macrophage surfaces depleted of CD91
(shown by reduction in attachment of Ebab-anti-CD91) but
also in CRT (shown by reduction of attachment of anti-
CRT Ebab). Plating macrophages onto wells coated with
control proteins did not modulate these receptors. Macro-
phages plated on either  2M or C1q tails showed dimin-
ished binding or uptake of Ebab coated with MBL, C1q,
C1q tails, or  2m (Ebab- 2m were also shown to be bound
and ingested by the macrophages). These macrophages
were still able to bind and ingest Ebab coated with anti-Fc
receptor antibody (anti-CD32 Ebab). Finally, modulation of
the macrophage receptors by plating the macrophages onto
wells coated with either  2m or C1q tails blocked uptake
of apoptotic cells. It seems reasonable to suggest that this
demonstration of a role for CD91 in collectin family medi-
ated ingestion of apoptotic cells may be extended to sys-
tems in which these innate immune system, pattern recog-
nition molecules participate in recognition and removal of
foreign organisms and cell debris.
We have recently provided evidence that uptake of ap-
optotic cells through the phosphatidylserine receptor is me-
diated by a process of macropinocytosis (unpublished data).
Data presented herein support the ability of CRT/CD91
ligation by C1q or MBL to induce macropinocytosis and
that this is the mechanism by which these collectin family
members initiate uptake of apoptotic cells. Thus anti-CRT
and anti-CD91 antibodies were shown to directly stimulate
macropinocytosis of the water soluble dye Lucifer Yellow.
Inclusion of this dye during uptake of apoptotic cells re-
sulted in simultaneous ingestion of apoptotic cell and dye
(data not shown). Similarly in these studies, Ebab coated
with anti-CRT were shown to be ingested in a fashion that
was accompanied by Lucifer Yellow uptake into the same
compartment. This could be contrasted with uptake of Ebab
via the Fc receptor. Finally, CRT and CD91 were shown
capable of mediating bystander uptake of attached cells into
macrophages. Erythrocytes coated with an anti-CD36 anti-
body were found to attach to the macrophage surface with-
out subsequent ingestion (Fig. 6 C). Antibody ligation of
either surface CRT or CD91 in this system was shown to
drive engulfment of the attached E (Fig. 6 B). The growth
factor M-CSF had the same effect on attached erythrocytes
(not shown). Antibodies to other surface molecules, in-
cluding anti-FcR, had no effect on uptake. In these systems
involving stimulation of CRT and CD91 with antibody,
crosslinking the primary antibody led to an enhanced ef-
fect. The multivalency of C1q and the collectins, as well as
their localized binding to the apoptotic cell surface, is in
keeping with this concept. Similarly, CD91 mediates en-
docytosis of  2m/proteinase complexes most effectively
when crosslinked (Fig. 6 A).
The ability of CRT and CD91 ligation to initiate mac-
ropinocytosis, therefore, suggests a mechanism for uptake
of apoptotic cells. It may also implicate macropinocytosis,
as well as CD91 involvement as an explanation for the
known ability of collectins to enhance phagocytosis of for-
eign particles and organisms (1, 52, 110). We also suspect
their similar participation in recognition and uptake of cell
debris during removal of damaged and necrotic cells. C1q
avidly binds via its globular head groups to free mitochon-
dria (128, 129). Pattern recognition by collectin family
members of the innate immune system could, by engaging
CRT and then CD91, provide significantly enhanced sig-
naling potential, not only quantitatively, but also, because
of the broad specificity of their globular head recognition
domains, to involve a very wide variety of ligands. Finally,
CD91 engagement has been shown to initiate maturation
of immature, dendritic cells (124) and enhancement of an-
tigen presentation (130).
C1q and MBL bind to and facilitate the ingestion of ap-
optotic cells by human macrophages. The structurally and
functionally similar collagenous tails of C1q and MBL bind
to CRT, which, in turn is bound to CD91 on the macro-
phage cell surface. Engagement of this receptor initiates a
process of macropinocytosis and eventual engulfment of
the apoptotic cell. This mechanism, which involves pattern
recognition molecules of the innate immune system, a
multifunctional cellular protein, and an evolutionarily con-
served clearance receptor, may be an ancient method the
body has evolved for ridding itself of a potentially harmful
source of self-antigen.
This work was supported by National Institutes of Health grants
GM 48211 and GM 61031.
Submitted: 28 November 2000
Revised: 17 July 2001
Accepted: 23 July 2001
References
1.Holmskov, U., R. Malhotra, R.B. Sim, and J.C. Jensenius.
1994. Collectins: collagenous C-type lectins of the innate
immune defense system. Immunol. Today. 15:67–74.
2.Hansen, S., and U. Holmskov. 1998. Structural aspects of
collectins and receptors for collectins. Immunobiology. 199:
165–189.
3.Loos, M., H. Martin, and F. Petry. 1989. The biosynthesis of
C1q, the collagen-like and Fc-recognizing molecule of the
complement system. Behring Inst. Mitt. 84:32-41.
4.Bowness, P., K.A. Davies, P.J. Norsworthy, P. Athanassiou,
J. Taylor-Wiedeman, L.K. Borysiewicz, P.A. Meyer, and
M.J. Walport. 1994. Hereditary C1q deficiency and sys-
temic lupus erythematosus. QJM. 87:455–464.
5.Carroll, M.C. 1998. The lupus paradox. Nat. Gen. 19:3–4.
6.Petry, F. 1998. Molecular basis of hereditary C1q deficiency.
Immunobiology. 199:286–294.
7.Stone, N.M., A. Williams, J.D. Wilkinson, and G. Bird.
2000. Systemic lupus erythematosus with C1q deficiency.792 C1q or MBL Mediate Macropinocytosis of Apoptotic Cells via CRT or CD91
Br. J. Dermatol. 142:521–524.
8.Tsao, B.P. 1998. Genetic susceptibility to lupus nephritis.
Lupus. 7:585–590.
9.Sullivan, K.E., C. Wooten, D. Goldman, and M. Petri.
1996. Mannose-binding protein genetic polymorphisms in
black patients with systemic lupus erythematosus. Arthritis
Rheum. 12:2046–2051.
10.Thomas, H.C., G.R. Foster, M. Sumiya, D. McIntosh, D.L.
Jack, M.W. Turner, and J.A. Summerfield. 1996. Mutation
of gene of mannose-binding protein associated with
chronic hepatitis B viral infection. Lancet. 348:1417–1419.
11.Davies, E.J., N. Snowden, M.C. Hillarby, D. Carthy, D.M.
Grennan, W. Thomson, and W.E. Ollier. 1995. Mannose-
binding protein gene polymorphism in systemic lupus
erythematosus. Arthritis Rheum. 38:110–114.
12.Gabolde, M., M. Guilloud-Bataille, J. Feingold, and C. Bes-
mond. 1999. Association of variant alleles of mannose
binding lectin with severity of pulmonary disease in cystic
fibrosis: cohort study. BMJ. 319:1166–1167.
13. Botto, M., C. Dell’Agnola, A.E. Bygrave, E.M. Thompson,
H.T. Cook, F. Petry, M. Loos, P.P. Pandolfi, and M.J.
Walport. 1998. Homozygous C1q deficiency causes glo-
merulonephritis associated with multiple apoptotic bodies.
Nat. Genet. 19:56–59.
14.Mevorach, D., J.L. Zhou, X. Song, and K.B. Elkon. 1998.
Systemic exposure to irradiated apoptotic cells induces au-
toantibody production. J. Exp. Med. 188:387–392.
15.Taylor, P.R., A. Carugati, V.A. Fadok, H.T. Cook, M. An-
drews, M.C. Carroll, J.S. Savill, P.M. Henson, M. Botto,
and M.J. Walport. 2000. A hierarchical role for classical
pathway complement proteins in the clearance of apoptotic
cells in vivo. J. Exp. Med. 192:359–366.
16.Korb, L.C., and J.M. Ahearn. 1997. C1q binds directly and
specifically to surface blebs of apoptotic human kerati-
nocytes: complement deficiency and systemic lupus ery-
thematosus revisited. J. Immunol. 158:4525–4528.
17.Navratil, J.S., S.C. Watkins, J.J. Wisnieski, and J.M. Ahearn.
2001. The globular heads of C1q specifically recognize sur-
face blebs of apoptotic vascular endothelial cells. J. Immu-
nol. 166:3231–3239.
18.Haslett, C., L.A. Guthrie, M.M. Kopaniak, R.B. Johnston,
Jr., and P.M. Henson. 1985. Modulation of multiple neu-
trophil functions by preparative methods or trace concen-
trations of bacterial lipopolysaccharide. Am. J. Pathol. 119:
101–110.
19.Fadok, V.A., M.L. Warner, D.L. Bratton, and P.M. Henson.
1998. CD36 is required for phagocytosis of apoptotic cells
by human macrophages that use either a phosphatidylserine
receptor or the vitronectin receptor (alpha v beta 3). J. Im-
munol. 161:6250–6257.
20.Ezekowitz, R.A., M. Kuhlman, J.E. Groopman, and R.A.
Byrn. 1989. A human serum mannose-binding protein in-
hibits in vitro infection by the human immunodeficiency
virus. J. Exp. Med. 169:185–196.
21.Reid, K.B. 1976. Isolation, by partial pepsin digestion, of the
three collagen-like regions present in subcomponent Clq of
the first component of human complement. Biochem. J.
155:5–17.
22.Duvall, E., A.H. Wyllie, and R.G. Morris. 1985. Macro-
phage recognition of cells undergoing programmed cell
death (apoptosis). Immunology. 56:351–358.
23.Dini, L., A. Lentini, G.D. Diez, M. Rocha, L. Falasca, L. Se-
rafino, and F. Vidal-Vanaclocha. 1995. Phagocytosis of ap-
optotic bodies by liver endothelial cells. J. Cell Sci. 108:
967–973.
24.Fadok, V.A., J.S. Savill, C. Haslett, D.L. Bratton, D.E.
Doherty, P.A. Campbell, and P.M. Henson. 1992. Differ-
ent populations of macrophages use either the vitronectin
receptor or the phosphatidylserine receptor to recognize
and remove apoptotic cells. J. Immunol. 149:4029–4035.
25.Fadok, V.A., and P.M. Henson. 1998. Apoptosis: getting rid
of the bodies. Curr. Biol. 8:R693–R695.
26.Savill, J., and V. Fadok. 2000. Corpse clearance defines the
meaning of cell death. Nature. 407:784–788.
27.Savill, J. 1997. Recognition and phagocytosis of cells under-
going apoptosis. Br. Med. Bull. 53:491–508.
28.Gregory, C.D., A. Devitt, and O. Moffatt. 1998. Roles of
ICAM-3 and CD14 in the recognition and phagocytosis of
apoptotic cells by macrophages. Biochem. Soc. Trans. 26:
644–649.
29.Moffatt, O.D., A. Devitt, E.D. Bell, D.L. Simmons, and
C.D. Gregory. 1999. Macrophage recognition of ICAM-3
on apoptotic leukocytes. J. Immunol. 162:6800–6810.
30.Devitt, A., O.D. Moffatt, C. Raykundalia, J.D. Capra, D.L.
Simmons, and C.D. Gregory. 1998. Human CD14 medi-
ates recognition and phagocytosis of apoptotic cells. Nature.
392:505–509.
31.Gregory, C.D. 2000. CD14-dependent clearance of apop-
totic cells: relevance to the immune system. Curr. Opin.
Immunol. 12:27–34.
32.Gregory, C.D. 2000. Non-inflammatory/anti-inflammatory
CD14 responses: CD14 in apoptosis. Chem. Immunol. 74:
122–140.
33.Ramprasad, M.P., W. Fischer, J.L. Witztum, G.R. Sam-
brano, O. Quehenberger, and D. Steinberg. 1995. The 94- to
97-kDa mouse macrophage membrane protein that recog-
nizes oxidized low density lipoprotein and phosphati-
dylserine-rich liposomes is identical to macrosialin, the
mouse homologue of human CD68. Proc. Natl. Acad. Sci.
USA. 92:9580–9584.
34.Haworth, R., N. Platt, S. Keshav, D. Hughes, E. Darley, H.
Suzuki, Y. Kurihara, T. Kodama, and S. Gordon. 1997.
The macrophage scavenger receptor type A is expressed by
activated macrophages and protects the host against lethal
endotoxic shock. J. Exp. Med. 186:1431–1439.
35.Platt, N., H. Suzuki, T. Kodama, and S. Gordon. 2000. Ap-
optotic thymocyte clearance in scavenger receptor class
A-deficient mice is apparently normal. J. Immunol. 164:
4861–4867.
36.Platt, N., H. Suzuki, Y. Kurihara, T. Kodama, and S. Gor-
don. 1996. Role for the class A macrophage scavenger re-
ceptor in the phagocytosis of apoptotic thymocytes in
vitro. Proc. Natl. Acad. Sci. USA. 93:12456–12460.
37.Shiratsuchi, A., and Y. Nakanishi. 1999. Elimination of un-
wanted cells by phagocytes. Seikagaku. 71:282–286.
38.Yamada, Y., T. Doi, T. Hamakubo, and T. Kodama. 1998.
Scavenger receptor family proteins: roles for atherosclero-
sis, host defence and disorders of the central nervous sys-
tem. Cell. Mol. Life Sci. 54:628–640.
39.Oka, K., T. Sawamura, K. Kikuta, S. Itokawa, N. Kume, T.
Kita, and T. Masaki. 1998. Lectin-like oxidized low-den-
sity lipoprotein receptor 1 mediates phagocytosis of aged/
apoptotic cells in endothelial cells. Proc. Natl. Acad. Sci.
USA. 95:9535–9540.
40.Ishimoto, Y., K. Ohashi, K. Mizuno, and T. Nakano. 2000.
Promotion of the uptake of PS liposomes and apoptotic793 Ogden et al.
cells by a product of growth arrest-specific gene, gas6. J.
Biochem. 127:411–417.
41.D’Cruz, P.M., D. Yasumura, J. Weir, M.T. Matthes, H. Ab-
derrahim, M.M. LaVail, and D. Vollrath. 2000. Mutation
of the receptor tyrosine kinase gene Mertk in the retinal
dystrophic RCS rat. Hum. Mol. Genet. 9:645–651.
42.Nandrot, E., E.M. Dufour, A.C. Provost, M.O. Pequignot,
S. Bonnel, K. Gogat, D. Marchant, C. Rouillac, B. Sepul-
chre de Conde, M.T. Bihoreau, et al. 2000. Homozygous
deletion in the coding sequence of the c-mer gene in RCS
rats unravels general mechanisms of physiological cell adhe-
sion and apoptosis. Neurobiol. Dis. 7:586–599.
43.Bondanza, A., M.G. Sabbadini, F. Pellegatta, V.S. Zimmer-
mann, A. Tincani, G. Balestrieri, A.A. Manfredi, and P.
Rovere. 2000. Anti-beta2 glycoprotein I antibodies pre-
vent the De-activation of platelets and sustain their phago-
cytic clearance. J. Autoimmun. 15:469–477.
44.Chan, A., T. Magnus, and R. Gold. 2001. Phagocytosis of
apoptotic inflammatory cells by microglia and modulation
by different cytokines: mechanism for removal of apoptotic
cells in the inflamed nervous system. Glia. 33:87–95.
45.Rovere, P., M.G. Sabbadini, C. Vallinoto, U. Fascio, M.
Recigno, M. Crosti, P. Ricciardi-Castagnoli, G. Bal-
estrieri, A. Tincani, and A.A. Manfredi. 1999. Dendritic
cell presentation of antigens from apoptotic cells in a proin-
flammatory context: role of opsonizing anti-beta2-glyco-
protein I antibodies. Arthritis Rheum. 42:1412–1420.
46.Mevorach, D., J.O. Mascarenhas, D. Gershov, and K.B.
Elkon. 1998. Complement-dependent clearance of apop-
totic cells by human macrophages. J. Exp. Med. 188:2313–
2320.
47.Fadok, V.A., D.L. Bratton, D.M. Rose, A. Pearson, R.A.
Ezekewitz, and P.M. Henson. 2000. A receptor for phos-
phatidylserine-specific clearance of apoptotic cells. Nature.
405:85–90.
48.Gigli, I., and R.A. Nelson, Jr. 1968. Complement depen-
dent immune phagocytosis. I. Requirements for C’1, C’4,
C’2, C’3. Exp. Cell Res. 51:45–67.
49.Stuart, G.R., N.J. Lynch, A.J. Day, W.J. Schwaeble, and
R.B. Sim. 1997. The C1q and collectin binding site within
C1q receptor (cell surface calreticulin). Immunopharmacol-
ogy. 38:73–80.
50.Eggleton, P., K.B. Reid, and A.J. Tenner. 1998. C1q—how
many functions? How many receptors? Trends Cell Biol.
8:428–431.
51.Tenner, A.J. 1998. C1q receptors: regulating specific func-
tions of phagocytic cells. Immunobiology. 199:250–264.
52.Nepomuceno, R.R., and A.J. Tenner. 1998. C1qRP, the
C1q receptor that enhances phagocytosis, is detected spe-
cifically in human cells of myeloid lineage, endothelial
cells, and platelets. J. Immunol. 160:1929–1935.
53.Braun, L., B. Ghebrehiwet, and P. Cossart. 2000. gC1q-R/
p32, a C1q-binding protein, is a receptor for the InlB inva-
sion protein of Listeria monocytogenes. EMBO J. 19:1458–
1466.
54.Bronson, R., S. Bronson, L. Oula, W. Zhang, and B. Ghe-
brehiwet. 1998. Detection of complement C1q receptors
on human spermatozoa. J. Reprod. Immunol. 38:1–14.
55.Bordin, S., B. Ghebrehiwet, and R.C. Page. 1990. Participa-
tion of C1q and its receptor in adherence of human diploid
fibroblast. J. Immunol. 145:2520–2526.
56.Bordin, S., M. Smith, B. Ghebrehiwet, D. Oda, and R.C.
Page. 1992. Smooth muscle and epithelial cells express spe-
cific binding sites for the C1q component of complement.
Clin. Immunol. Immunopathol. 63:51–57.
57.Crouch, E., K. Hartshorn, and I. Ofek. 2000. Collectins and
pulmonary innate immunity. Immunol. Rev. 173:52–65.
58.Dedio, J., W. Jahnen-Dechent, M. Bachmann, and W.
Muller-Esterl. 1998. The multiligand-binding protein
gC1qR, a putative C1q receptor, is a mitochondrial pro-
tein. J. Immunol. 160:3534–3542.
59.Erdei, A., and K.B. Reid. 1988. The C1q receptor. Mol. Im-
munol. 25:1067–1073.
60.Erdei, A., and K.B. Reid. 1989. Characterization of the hu-
man C1q receptor. Behring Inst. Mitt. 84:216-219.
61.Erdei, A. 1990. C1q receptor on murine cells. J. Immunol.
145:1754–1760.
62.Eggleton, P., B. Ghebrehiwet, K.N. Sastry, J.P. Coburn,
K.S. Zaner, K.B. Reid, and A.I. Tauber. 1995. Identifica-
tion of a gC1q-binding protein (gC1q-R) on the surface of
human neutrophils. Subcellular localization and binding
properties in comparison with the cC1q-R. J. Clin. Invest.
95:1569–1578.
63.Fusi, F., R.A. Bronson, Y. Hong, and B. Ghebrehiwet.
1991. Complement component C1q and its receptor are
involved in the interaction of human sperm with zona-free
hamster eggs. Mol. Reprod. Dev. 29:180–188.
64.Ghebrehiwet, B., P.D. Lu, W. Zhang, S.A. Keilbaugh, L.E.
Leigh, P. Eggleton, K.B. Reid, and E.I. Peerschke. 1997.
Evidence that the two C1q binding membrane proteins,
gC1q-R and cC1q-R, associate to form a complex. J. Im-
munol. 159:1429–1436.
65.Ghebrehiwet, B. 1987. C1q receptor. Methods Enzymol. 150:
558–578.
66.Ghebrehiwet, B., and E.I. Peerschke. 1998. Structure and
function of gC1q-R: a multiligand binding cellular pro-
tein. Immunobiology. 199:225–238.
67.Kaul, M., and M. Loos. 1995. Collagen-like complement
component C1q is a membrane protein of human mono-
cyte-derived macrophages that mediates endocytosis. J. Im-
munol. 155:5795–5802.
68.Jack, R.M., B.A. Lowenstein, and A. Nicholson-Weller.
1994. Regulation of C1q receptor expression on human
polymorphonuclear leukocytes. J. Immunol. 153:262–269.
69.Klickstein, L.B., S.F. Barbashov, T. Liu, R.M. Jack, and A.
Nicholson-Weller. 1997. Complement receptor type 1
(CR1, CD35) is a receptor for C1q. Immunity. 7:345–355.
70.Lim, B.L., K.B. Reid, B. Ghebrehiwet, E.I. Peerschke, L.A.
Leigh, and K.T. Preissner. 1996. The binding protein for
globular heads of complement C1q, gC1qR. Functional
expression and characterization as a novel vitronectin bind-
ing factor. J. Biol. Chem. 271:26739–26744.
71.Lim, B.L., R.A. White, G.S. Hummel, W. Schwaeble, N.J.
Lynch, E.I. Peerschke, K.B. Reid, and B. Ghebrehiwet.
1998. Characterization of the murine gene of gC1qBP, a
novel cell protein that binds the globular heads of C1q, vit-
ronectin, high molecular weight kininogen and factor XII.
Gene. 209:229–237.
72.Lurton, J., H. Soto, A.S. Narayanan, and G. Raghu. 1999.
Regulation of human lung fibroblast C1q-receptors by
transforming growth factor-beta and tumor necrosis factor-
alpha. Exp. Lung Res. 25:151–164.
73.Lynch, N.J., K.B. Reid, R.H. van den Berg, M.R. Daha,
L.A. Leigh, B. Ghebrehiwet, W.B. Lim, and W.J. Schwae-
ble. 1997. Characterisation of the rat and mouse homo-
logues of gC1qBP, a 33 kDa glycoprotein that binds to the794 C1q or MBL Mediate Macropinocytosis of Apoptotic Cells via CRT or CD91
globular ‘heads’ of C1q. FEBS Lett. 418:111–114.
74.Malhotra, R., S. Thail, K.B.M. Reid, and R.B. Sim. 1990.
Human leukocyte C1q receptor binds other soluble pro-
teins with collagen domains. J. Exp. Med. 172:955–959.
75.Malhotra, R., A.C. Willis, J.-C. Jensenius, J. Jackson, and
R.B. Sim. 1993. Structure and homology of the human
C1q receptor. Immunology. 78:341–348.
76.Malhotra, R., S.B. Laursen, A.C. Willis, and R.B. Sim.
1993. Localization of the receptor-binding site in the col-
lectin family of proteins. Biochem. J. 293:15–19.
77.Malhotra, R., J. Lu, U. Holmskov, and R.B. Sim. 1994.
Collectins, collectin receptors and the lectin pathway of
complement activation. Clin. Exp. Immunol. 97(Suppl 2):
4–9.
78.Michalak, M., E.F. Corbett, N. Mesaeli, K. Nakamura, and
M. Opas. 1999. Calreticulin: one protein, one gene, many
functions. Biochem. J. 344:281–292.
79.Narayanan, A.S., J. Lurton, and G. Raghu. 1997. Distribu-
tion of receptors to collagen and globular domains of C1q
in human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 17:
84–90.
80.Nepomuceno, R.P., A.H. Henscen-Edman, W.H. Burgess,
and A.J. Tenner. 1997. cDNA cloning and primary struc-
ture analysis of C1qRp, the human C1q/MBP/SPA recep-
tor that mediates enhanced phagocytosis in vitro. Immunity.
6:119–129.
81.Nguyen, T., B. Ghebrehiwet, and E.I. Peerschke. 2000. Staph-
ylococcus aureus protein A recognizes platelet gC1qR/p33: a
novel mechanism for staphylococcal interactions with
platelets. Infect. Immun. 68:2061–2068.
82.Peerschke, E.I., and B. Ghebrehiwet. 1990. Platelet C1q re-
ceptor interactions with collagen- and C1q-coated sur-
faces. J. Immunol. 145:2984–2988.
83.Peerschke, E.I., and B. Ghebrehiwet. 1990. Modulation of
platelet responses to collagen by Clq receptors. J. Immunol.
144:221–225.
84.Peerschke, E.I., R. Malhotra, B. Ghebrehiwet, K.B. Reid,
A.C. Willis, and R.B. Sim. 1993. Isolation of a human en-
dothelial cell C1q receptor (C1qR). J. Leukoc. Biol. 53:
179–184.
85.Peerschke, E.I., K.B. Reid, and B. Ghebrehiwet. 1994.
Identification of a novel 33-kDa C1q-binding site on hu-
man blood platelets. J. Immunol. 152:5896–5901.
86.Peerschke, E.I., S.S. Smyth, E.I. Teng, M. Dalzell, and B.
Ghebrehiwet. 1996. Human umbilical vein endothelial
cells possess binding sites for the globular domain of C1q.
J. Immunol. 157:4154–4158.
87.Peterson, K.L., W. Zhang, P.D. Lu, S.A. Keilbaugh, E.I.
Peerschke, and B. Ghebrehiwet. 1997. The C1q-binding
cell membrane proteins cC1q-R and gC1q-R are released
from activated cells: subcellular distribution and immu-
nochemical characterization. Clin. Immunol. Immunopathol.
84:17–26.
88.Sim, R.B., S.K. Moestrup, G.R. Stuart, N.J. Lynch, J. Lu,
W.J. Schwaeble, and R. Malhotra. 1998. Interaction of
C1q and the collectins with the potential receptors calre-
ticulin (cC1qR/collectin receptor) and megalin. Immunobi-
ology. 199:208–224.
89.Tenner, A.J., S.L. Robinson, and R.A. Ezekowitz. 1995.
Mannose binding protein (MBP) enhances mononuclear
phagocyte function via a receptor that contains the 126,000
Mr component of the C1q receptor. Immunity. 3:485–493.
90.Van Den Berg, R.H., C.E.H. Siegert, M.C. Faber-Krol,
T.W.J. Huizinga, L.A. Van Es, and M.R. Daha. 1998.
Anti-C1q receptor/calreticulin autoantibodies in patients
with systemic lupus erythematosus (SLE). Clin. Exp. Immu-
nol. 111:359–364.
91.Mevorach, D. 2000. Opsonization of apoptotic cells. Impli-
cations for uptake and autoimmunity. Ann. NY Acad. Sci.
926:226–235.
92.Coppolino, M.G., M.J. Woodside, N. Demaurex, S. Grin-
stein, R. St-Arnaud, and S. Dedhar. 1997. Calreticulin is
essential for integrin-mediated calcium signalling and cell
adhesion. Nature. 386:843–847.
93.Coppolino, M.G., and S. Dedhar. 1998. Calreticulin. Int. J.
Biochem. Cell Biol. 30:553–558.
94.Coppolino, M.G., and S. Dedhar. 1999. Ligand-specific,
transient interaction between integrins and calreticulin
during cell adhesion to extracellular matrix proteins is de-
pendent upon phosphorylation/dephosphorylation events.
Biochem. J. 340:41–50.
95.Coppolino, M.G., and S. Dedhar. 2000. Bi-directional signal
transduction by integrin receptors. Int. J. Biochem. Cell Biol.
32:171–188.
96.Arosa, F.A., O. de Jesus, G. Porto, A.M. Carmo, and M. de
Sousa. 1999. Calreticulin is expressed on the cell surface of
activated human peripheral blood T lymphocytes in associ-
ation with major histocompatibility complex class I mole-
cules. J. Biol. Chem. 274:16917–16922.
97.Eggleton, P., A.J. Tenner, and K.B. Reid. 2000. C1q recep-
tors. Clin. Exp. Immunol. 120:406–412.
98.Basu, S., R.J. Binder, T. Ramalingam, and P.K. Srivastava.
2001. CD91 is a common receptor for heat shock proteins
gp96, hsp90, hsp70, and calreticulin. Immunity. 14:303–
313.
99.Racoosin, E.L., and J.A. Swanson. 1993. Macropinosome
maturation and fusion with tubular lysosomes in macro-
phages. J. Cell Biol. 121:1011–1020.
100.Racoosin, E.L., and J.A. Swanson. 1992. M-CSF-induced
macropinocytosis increases solute endocytosis but not re-
ceptor-mediated endocytosis in mouse macrophages. J.
Cell Sci. 102:867–880.
101.Racoosin, E.L., and J.A. Swanson. 1989. Macrophage col-
ony-stimulating factor (rM-CSF) stimulates pinocytosis in
bone marrow–derived macrophages. J. Exp. Med. 170:
1635–1648.
102.Hewlett, L.J., A.R. Prescott, and C. Watts. 1994. The
coated pit and macropinocytic pathways serve distinct en-
dosome populations. J. Cell Biol. 124:689–703.
103.Griffin, F.M., J.A. Griffin, J.E. Leider, and S.C. Silverstein.
1975. Studies on the mechanism of phagocytosis. I. Re-
quirements for circumferential attachment of particle-
bound ligands to specific receptors on the macrophage
plasma membrane. J. Exp. Med. 142:1263–1282.
104.Griffin, F.M., J.A. Griffin, and S.C. Silverstein. 1976. Stud-
ies on the mechanism of phagocytosis. II. The interaction
of macrophages with anti-immunoglobulin IgG-coated
bone marrow–derived lymphocytes. J. Exp. Med. 144:788–
809.
105.Schagat, T.L., J.A. Wofford, and J.R. Wright. 2001. Surfac-
tant protein A enhances alveolar macrophage phagocytosis
of apoptotic neutrophils. J. Immunol. 166:2727–2733.
106.Bradley, A.J., D.E. Brooks, R. Norris-Jones, and D.V. De-
vine. 1999. C1q binding to liposomes is surface charge de-
pendent and is inhibited by peptides consisting of residues
14-26 of the human C1qA chain in a sequence indepen-795 Ogden et al.
dent manner. Biochim. Biophys. Acta. 1418:19–30.
107.Chen, A., S. Gaddipati, Y. Hong, D.J. Volkman, E.I. Peer-
schke, and B. Ghebrehiwet. 1994. Human T cells express
specific binding sites for C1q. Role in T cell activation and
proliferation. J. Immunol. 153:1430–1440.
108.Ghebrehiwet, B., G.S. Habicht, and G. Beck. 1990. Interac-
tion of C1q with its receptor on cultured cell lines induces
an anti-proliferative response. Clin. Immunol. Immunopathol.
54:148–160.
109.Goodman, E.B., and A.J. Tenner. 1992. Signal transduction
mechanisms of C1q-mediated superoxide production. Evi-
dence for the involvement of temporally distinct staurospo-
rine-insensitive and sensitive pathways. J. Immunol. 148:
3920–3928.
110.Guan, E.N., W.H. Burgess, S.L. Robinson, E.B. Goodman,
K.J. McTigue, and A.J. Tenner. 1991. Phagocytic cell
molecules that bind the collagen-like region of C1q. In-
volvement in the C1q-mediated enhancement of phagocy-
tosis. J. Biol. Chem. 266:20345–20355.
111.Kovacs, H., I.D. Campbell, P. Strong, S. Johnson, F.J.
Ward, K.B. Reid, and P. Eggleton. 1998. Evidence that
C1q binds specifically to CH2-like immunoglobulin
gamma motifs present in the autoantigen calreticulin and
interferes with complement activation. Biochemistry. 37:
17865–17874.
112.Tan, X., S.T. Wong, B. Ghebrehiwet, D.R. Storm, and S.
Bordin. 1998. Complement C1q inhibits cellular spreading
and stimulates adenylyl cyclase activity of fibroblasts. Clin.
Immunol. Immunopathol. 87:193–204.
113.Dini, L. 1998. Endothelial liver cell recognition of apoptotic
peripheral blood lymphocytes. Biochem. Soc. Trans. 26:635–
639.
114.Dini, L. 2000. Recognizing death: liver phagocytosis of ap-
optotic cells. Eur. J. Histochem. 44:217–227.
115.Ruzittu, M., E.C. Carla, M.R. Montinari, G. Maietta, and
L. Dini. 1999. Modulation of cell surface expression of
liver carbohydrate receptors during in vivo induction of
apoptosis with lead nitrate. Cell Tissue Res. 298:105–112.
116.Tsuji, S., K. Kaji, and S. Nagasawa. 1994. Activation of the
alternative pathway of human complement by apoptotic
human umbilical vein endothelial cells. J. Biochem. 116:
794–800.
117.Gershov, D., S. Kim, N. Brot, and K.B. Elkon. 2000.
C-Reactive protein binds to apoptotic cells, protects the
cells from assembly of the terminal complement compo-
nents, and sustains an antiinflammatory innate immune re-
sponse: implications for systemic autoimmunity. J. Exp.
Med. 192:1353–1364.
118.Fadok, V.A., D.L. Bratton, S.C. Frasch, M.L. Warner, and
P.M. Henson. 1998. The role of phosphatidylserine in rec-
ognition of apoptotic cells by phagocytes. Cell Death Differ.
5:551–562.
119.Savill, J.S., P.M. Henson, and C. Haslett. 1989. Phagocytosis
of aged human neutrophils by macrophages is mediated by
a novel “charge-sensitive” recognition mechanism. J. Clin.
Invest. 84:1518–1527.
120.Stuart, G.R., N.J. Lynch, J. Lu, A. Geick, B.E. Moffatt,
R.B. Sim, and W.J. Schwaeble. 1996. Localisation of the
C1q binding site within C1q receptor/calreticulin. FEBS
Lett. 397:245–249.
121.Peerschke, E.I.B., K.B.M. Reid, and B. Ghebrehiwet. 1994.
Identification of a novel 33-kDa binding site on human
platelets. J. Immunol. 152:5896–5901.
122.Sengelov, H. 1995. Complement receptors in neutrophils.
Crit. Rev. Immunol. 15:107–131.
123.Dougherty, G.J., and W.H. McBride. 1984. Macrophage
heterogeneity. J. Clin. Lab. Immunol. 14:1–11.
124.Basu, S., R.J. Binder, R. Suto, K.M. Anderson, and P.K.
Srivastava. 2000. Necrotic but not apoptotic cell death re-
leases heat shock proteins, which deliver a partial matura-
tion signal to dendritic cells and activate the NF-kappaB
pathway. Int. Immunol. 12:1539–1546.
125.Gliemann, J., A. Nykjaer, C.M. Petersen, K.E. Jorgensen,
M. Nielsen, P.A. Andreasen, E.I. Christensen, A. Lookene,
G. Olivecrona, and S.K. Moestrup. 1994. The multiligand
alpha 2-macroglobulin receptor/low density lipoprotein
receptor-related protein (alpha 2MR/LRP). Binding and
endocytosis of fluid phase and membrane-associated
ligands. Ann. NY Acad. Sci. 737:20–38.
126.Zhou, Z., E. Hartwieg, and H.R. Horvitz. 2001. CED-1 is a
transmembrane receptor that mediates cell corpse engulf-
ment in C. elegans. Cell. 104:43–56.
127.Ellis, R.E., D.M. Jacobson, and H.R. Horvitz. 1991. Genes
required for the engulfment of cell corpses during pro-
grammed cell death in Caenorhabditis elegans. Genetics. 129:
79–94.
128.Arend, W.P., R.J. Massoni, M.A. Niemann, and P.C. Gi-
clas. 1989. Absence of induction of IL-1 production in hu-
man monocytes by complement fragments. J. Immunol.
142:173–178.
129.Pinckard, R.N., M.S. Olson, P.C. Giclas, R. Terry, J.T.
Boyer, and R.A. O’Rourke. 1975. Consumption of classi-
cal complement components by heart subcellular mem-
branes in vitro and in patients after acute myocardial infarc-
tion. J. Clin. Invest. 56:740–750.
130.Binder, R.J., D.K. Han, and P.K. Srivastava. 2000. CD91: a
receptor for heat shock protein gp96. Nat. Immunol. 1:151–
155.